Franklin Resources Inc. continued to hold its stake in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,182,185 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Franklin Resources Inc. owned 9.93% of Marinus Pharmaceuticals worth $2,990,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. KCG Holdings Inc. grew its stake in shares of Marinus Pharmaceuticals by 29.5% during the 1st quarter. KCG Holdings Inc. now owns 64,539 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 14,692 shares during the period. Nexthera Capital LP acquired a new stake in shares of Marinus Pharmaceuticals during the 1st quarter worth approximately $1,416,000. Finally, Jennison Associates LLC grew its stake in shares of Marinus Pharmaceuticals by 108.1% during the 2nd quarter. Jennison Associates LLC now owns 811,665 shares of the biopharmaceutical company’s stock worth $1,112,000 after purchasing an additional 421,600 shares during the period. 23.61% of the stock is currently owned by institutional investors and hedge funds.

Marinus Pharmaceuticals, Inc. (NASDAQ MRNS) opened at 5.87 on Friday. Marinus Pharmaceuticals, Inc. has a 12 month low of $0.82 and a 12 month high of $5.97. The stock’s 50 day moving average price is $2.95 and its 200-day moving average price is $1.82. The stock’s market cap is $153.06 million.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.06. Equities research analysts predict that Marinus Pharmaceuticals, Inc. will post ($0.74) EPS for the current year.

A number of brokerages have recently commented on MRNS. ValuEngine raised shares of Marinus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, July 25th. JMP Securities reaffirmed an “outperform” rating and set a $11.00 price objective (up previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Tuesday, September 12th.

WARNING: “Franklin Resources Inc. Maintains Holdings in Marinus Pharmaceuticals, Inc. (MRNS)” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at

Marinus Pharmaceuticals Profile

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Want to see what other hedge funds are holding MRNS? Visit to get the latest 13F filings and insider trades for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS).

Institutional Ownership by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.